Financings in Brief: Calypte Biomedical
This article was originally published in The Gray Sheet
Executive Summary
Calypte Biomedical: Nets about $14.1 mil. from initial public offering of 2.5 mil. shares of common stock, including 236,259 overallotment shares, at $6 each. Pacific Growth Equities was managing underwriter for the offering ("The Gray Sheet" July 1, p. 13). The firm received FDA approval for its Calypte HIV-1 Urine EIA urine-based HIV-1 screening test on Aug. 6 ("The Gray Sheet" Aug. 12, p. 3)...